Paul Barr, MD
Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NYAuthored Items
Jillian Settlemire, RN, Jocelyn E. Bushart, ANP-BC, Sandra Dai, PhD, MS, James P. Dean, MD, PhD, David Arthur, PhD, Paul Barr, MD, Steven Coutre, MD
October 25, 2019 | November 2019 Vol 10, No 11
Ibrutinib, a first-in-class, once-daily inhibitor of Bruton tyrosine kinase (BTK), is approved in the US for the treatment of CLL/SLL and allows for treatment without chemotherapy.
Last modified: December 17, 2021